Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on Curis and keeping the price target at $17.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sara Nik’s rating is based on Curis’s promising financial and clinical developments. The company reported better-than-expected financial results for the second quarter of 2025, with an EPS that surpassed both the firm’s and consensus estimates. Additionally, Curis’s lead asset, emavusertib, is progressing through multiple clinical trials, showcasing its potential as a first-in-class oral inhibitor for various cancer types, including Non-Hodgkins Lymphoma and Acute Myeloid Leukemia.
Curis is also expanding the application of emavusertib into Chronic Lymphocytic Leukemia, a market with significant unmet needs. This strategic move is expected to enhance the drug’s profile and market opportunity. With a solid cash position and a clear plan to advance its clinical programs, Curis is well-positioned for future growth, justifying the Buy rating from Sara Nik.